Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus

Zydus to disrupt GLP-1 market with day-1 launch of innovative Semaglutide in India

Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights

NATCO receives CDSCO approval for Semaglutide in India

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus

Zydus receives FDA’s tentative approval for Dapagliflozin Tablets

Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India

Company to launch product after the expiry of semaglutide patent in India

Cipla launches needle-free inhalable insulin Afrezza in India

Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge

Emcure Pharma launches weight loss drug Poviztra in India

Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management

Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes in India

Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

Zydus receives FDA’s tentative approval for Empagliflozin and Linagliptin tablets

J&J MedTech reports strong one-year results for shockwave peripheral IVL system in DISRUPT BTK II trial

The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year